Last reviewed · How we verify

NCT03170830

Diagnostic Value of CircRNA-Uck2 for Acute Myocardial Infarction

Status unknown NA Last updated 31 May 2017
What this trial tests

NA trial testing the diagnosis value of cUck2 in acute myocardial infarction. in Cardiac Disease in 178 participants. Status unknown.

Timeline
1 August 2015
Primary endpoint
31 December 2018
31 December 2018

Quick facts

Lead sponsorBeijing Haidian Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposediagnostic
Enrollment178
Start date1 August 2015
Primary completion31 December 2018
Estimated completion31 December 2018
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Haidian Hospital

Who can join

18 and older, any sex, with Cardiac Disease or Diagnoses Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational diagnostic study that aims to evaluate the diagnostic value of circRNA-Uck2 in Acute Myocardial Infarction (AMI) in adults as compared to healthy and unstable angina controls. Rapid and adequate diagnosis of AMI is of great importance to enable a rapid start of treatment, save large tracts of dying myocardium, reduce the infarct size,and thereby decrease the risk of subsequent heart failure.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Roles of circular RNA in breast cancer: present and future.
    Li Z, Chen Z, Hu G, Jiang Y. · · 2019 · cited 76× · PMID 31396311
  2. The emerging role and significance of circular RNAs in viral infections and antiviral immune responses: possible implication as theranostic agents.
    Awan FM, Yang BB, Naz A, Hanif A, et al · · 2021 · cited 53× · PMID 32615049 · DOI 10.1080/15476286.2020.1790198
  3. A Dual-Circular RNA Signature as a Non-invasive Diagnostic Biomarker for Gastric Cancer.
    Han L, Zhang X, Wang A, Ji Y, et al · · 2020 · cited 18× · PMID 32154178 · DOI 10.3389/fonc.2020.00184
  4. Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: The Path From Bench to Bedside.
    Zhou LY, Lin SN, Rieder F, Chen MH, et al · · 2021 · cited 11× · PMID 33324986 · DOI 10.1093/ibd/izaa321
  5. Circular RNAs in the Origin of Developmental Lung Disease: Promising Diagnostic and Therapeutic Biomarkers.
    Tong Y, Zhang S, Riddle S, Song R, et al · · 2023 · cited 8× · PMID 36979468 · DOI 10.3390/biom13030533
  6. Hints From the Cellular Functions to the Practical Outlook of Circular RNAs.
    Yesharim L, Mojbafan M, Abiri M. · · 2021 · cited 7× · PMID 34220952 · DOI 10.3389/fgene.2021.679446
  7. Circular RNAs in Cardiovascular Physiopathology: From Molecular Mechanisms to Therapeutic Opportunities.
    Capirossi G, Brasini S, Tremoli E, Binatti A, et al · · 2025 · cited 1× · PMID 41096990 · DOI 10.3390/ijms26199725
  8. Decoding the regulatory roles of circular RNAs in cardiac fibrosis.
    You Q, Yu J, Pan R, Feng J, et al · · 2025 · cited 1× · PMID 39759175 · DOI 10.1016/j.ncrna.2024.11.007

Verify or expand the search:

Other recruiting trials for Cardiac Disease

Currently open trials in the same condition.

Other Beijing Haidian Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03170830.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing